Repair of endothelial glycocalyx
The use of glycosaminoglycan components in a composition addresses the issue of endothelial glycocalyx dysfunction in organ transplantation, enhancing organ function and reducing the risk of primary graft dysfunction.
WO2025085476A1 Publication Date: 2025-04-24UNITED THERAPEUTICS CORP
5 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/051508
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-17
- Filing Date
- 2024-10-16
- Publication Date
- 2025-04-24
AI Technical Summary
Technical Problem
Organ transplantation, particularly lung transplantation, is limited by primary graft dysfunction (PGD) due to endothelial glycocalyx (EG) dysfunction, which leads to vascular permeability and reduced organ function.
Method used
A composition comprising glycosaminoglycan components, such as high molecular weight hyaluronic acid and sulodexide, is administered to improve tissue and organ function by enhancing EG integrity.
Benefits of technology
The administration of glycosaminoglycan components reduces markers of endothelial damage and activation, thereby improving lung function and reducing the risk of primary graft dysfunction during organ transplantation.
✦ Generated by Eureka AI based on patent content.
Abstract
Compositions and methods relating to glycosaminoglycan components are disclosed. For example, a composition including glycosaminoglycan components are administered to organs before, during, or after ex vivo organ perfusion to improve organ transplantation. The improvements include reduced MMP levels, reduced apoptotic markers, reduced endothelial activation, and increased organ function. Such methods and compositions are useful for organ and tissue transplantation and storage or shipment of harvested organs and tissues.
Need to check novelty before this filing date? Find Prior Art